Law Firm Investigates Pacira BioSciences Over Shareholder Rights
Monteverde & Associates PC has opened an investigation into Pacira BioSciences, flagging potential shareholder concerns at the NASDAQ-listed drugmaker.
A New York-based class action law firm has announced an investigation into Pacira BioSciences, Inc. (NASDAQ: PCRX), raising questions about whether shareholders of the pharmaceutical company have had their interests adequately protected, according to a notice issued by Monteverde & Associates PC.
Attorney Juan Monteverde, who leads the firm, said the investigation is underway, though the notice did not specify the precise nature of the alleged shareholder harm or identify a triggering corporate event such as a merger, acquisition, or executive decision. Monteverde & Associates has been ranked among the Top 50 firms in the 2025 ISS Securities Class Action Services Report and has previously recovered millions of dollars on behalf of investors in similar matters.
Read more Law Firm Probes Option Care Health Amid Shareholder Concerns →
Pacira BioSciences, listed on the NASDAQ exchange under the ticker PCRX, is a specialty pharmaceutical company. Shareholder investigations of this nature typically precede formal litigation and are intended to determine whether corporate officers, directors, or deal counterparties may have breached fiduciary duties owed to investors.
Shareholders who hold or recently held a position in PCRX and wish to learn more about their legal rights are generally encouraged to contact the investigating firm directly before any court-imposed deadline. The outcome of preliminary investigations varies widely — some result in formal class action lawsuits while others are closed without further action.
Continue reading at All Financial Services & Investing.
